Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.

Foloppe J, Kempf J, Futin N, Kintz J, Cordier P, Pichon C, Findeli A, Vorburger F, Quemeneur E, Erbs P.

Mol Ther Oncolytics. 2019 Mar 27;14:1-14. doi: 10.1016/j.omto.2019.03.005. eCollection 2019 Sep 27.

2.

By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.

Kleinpeter P, Remy-Ziller C, Winter E, Gantzer M, Nourtier V, Kempf J, Hortelano J, Schmitt D, Schultz H, Geist M, Brua C, Hoffmann C, Schlesinger Y, Villeval D, Thioudellet C, Erbs P, Foloppe J, Silvestre N, Fend L, Quemeneur E, Marchand JB.

J Virol. 2019 May 15;93(11). pii: e00207-19. doi: 10.1128/JVI.00207-19. Print 2019 Jun 1.

3.

Oncolytic properties of non-vaccinia poxviruses.

Ricordel M, Foloppe J, Pichon C, Findeli A, Tosch C, Cordier P, Cochin S, Quémeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Oncotarget. 2018 Nov 13;9(89):35891-35906. doi: 10.18632/oncotarget.26288. eCollection 2018 Nov 13.

4.

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency.

Ricordel M, Foloppe J, Antoine D, Findeli A, Kempf J, Cordier P, Gerbaud A, Grellier B, Lusky M, Quemeneur E, Erbs P.

Cancers (Basel). 2018 Jul 10;10(7). pii: E231. doi: 10.3390/cancers10070231.

5.

Ultrasound-mediated cavitation does not decrease the activity of small molecule, antibody or viral-based medicines.

Myers R, Grundy M, Rowe C, Coviello CM, Bau L, Erbs P, Foloppe J, Balloul JM, Story C, Coussios CC, Carlisle R.

Int J Nanomedicine. 2018 Jan 10;13:337-349. doi: 10.2147/IJN.S141557. eCollection 2018.

6.

Cowpox Virus: A New and Armed Oncolytic Poxvirus.

Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, Cochin S, Cordier P, Quemeneur E, Camus-Bouclainville C, Bertagnoli S, Erbs P.

Mol Ther Oncolytics. 2017 Aug 24;7:1-11. doi: 10.1016/j.omto.2017.08.003. eCollection 2017 Dec 15.

7.

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.

Myers R, Coviello C, Erbs P, Foloppe J, Rowe C, Kwan J, Crake C, Finn S, Jackson E, Balloul JM, Story C, Coussios C, Carlisle R.

Mol Ther. 2016 Sep;24(9):1627-33. doi: 10.1038/mt.2016.139. Epub 2016 Jul 4.

8.

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

Fend L, Remy-Ziller C, Foloppe J, Kempf J, Cochin S, Barraud L, Accart N, Erbs P, Fournel S, Préville X.

Oncoimmunology. 2015 Oct 6;5(2):e1080414. eCollection 2016 Feb.

9.

Oncolytic immunotherapy: The new clinical outbreak.

Fonteneau JF, Achard C, Zaupa C, Foloppe J, Erbs P.

Oncoimmunology. 2015 Aug 12;5(1):e1066961. eCollection 2016. No abstract available.

10.

Oncolytic vaccinia virus: a silver bullet?

Lusky M, Erbs P, Foloppe J, Acres RB.

Expert Rev Vaccines. 2010 Dec;9(12):1353-6. doi: 10.1586/erv.10.137. No abstract available.

PMID:
21105770
11.

Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.

Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A.

Clin Cancer Res. 2010 May 1;16(9):2540-9. doi: 10.1158/1078-0432.CCR-09-2974. Epub 2010 Apr 13.

Supplemental Content

Loading ...
Support Center